TB-500 in women: what the research actually shows

Last updated 2026-07-25

Is there any research on TB-500 specifically in women?

No. There is no published clinical study that isolates female subjects and tests TB-500 against a control group. What you find in the literature is a small stack of preclinical and analytical chemistry papers, mostly about detecting the peptide in doping samples, plus a handful of orthopaedic review articles that mention peptide therapies in general terms. A 2024 paper in the Journal of Chromatography B did quantify TB-500 and its metabolites in rats and screened wound-healing activity in vitro ^[1]. That's rodent and cell-culture data, not human data, and the paper does not report sex as a variable of interest in the way you'd want for a "does this work differently in women" question. The 2026 orthopaedic literature (a review in JAAOS Global Research & Reviews and a primer in The American Journal of Sports Medicine) discusses peptide therapies used in sports medicine and orthopaedics generally, without breaking findings out by sex ^{[2] [3]}. A 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries covers safety and efficacy questions across the class, again without a female-specific subgroup ^[4]. If someone tells you they've found a study proving TB-500 works differently, better, or worse in women, ask them to link it. It doesn't exist yet.

What's the difference between TB-500 and native thymosin beta-4?

This distinction matters more than most sourcing pages let on. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found throughout the human body, involved in actin regulation and cell migration. TB-500 is not that protein. It's a synthetic peptide built around a smaller active fragment of Tβ4, and the analytical literature is explicit about this distinction because it matters for detection and identification. A 2012 paper in Drug Testing and Analysis describes the synthesis and characterization of "the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500" ^[5], meaning TB-500 as sold is built around a 7-amino-acid piece of the parent molecule, not the full 43-residue protein. Chromatography and mass spectrometry papers used for doping control treat TB-500 as its own analyte precisely because it is not chemically identical to endogenous Tβ4 ^{[6] [7]}. So when a product listing or forum post uses "TB-500" and "thymosin beta-4" interchangeably, that's sloppy at best. The research base for each is different, and studies on native Tβ4's role in wound healing or aging biology (like a 2026 Frontiers in Aging paper on therapeutic peptides in gerontology ^[8]) don't automatically transfer to claims about the synthetic fragment product. If you're comparing the two compounds side by side before deciding anything, BPC-157 vs TB-500 walks through mechanism differences in more depth. It's also worth reading before you start comparing dosing protocols across compounds, since the mechanisms are not interchangeable even though people talk about them that way.

Does TB-500 affect hormones, menstrual cycle, or fertility?

Nobody has published data on this. Not in animals stratified by sex, and not in humans. The existing preclinical work on TB-500 focuses on wound-healing activity in vitro and pharmacokinetics in rats ^[1], not on reproductive endocrinology or menstrual cycle interaction. This is an honest gap, not a reassurance. The absence of a documented hormonal effect is not the same as evidence the peptide has no hormonal effect. It just means the specific study hasn't been run and published. If you're pregnant, trying to conceive, or breastfeeding, you're in a data vacuum, and any dosing decision there is made without a research safety net under it. The same applies to interaction with hormonal birth control, HRT, or fertility medications. There's no pharmacokinetic study examining whether TB-500's metabolism is altered by concurrent hormone therapy. The 2024 chromatography paper that quantified TB-500 metabolites in rats ^[1] is the closest thing to a metabolic profile that exists, and it says nothing about hormone interaction.

Is TB-500 dosed differently for women than men?

There is no published dosing protocol for TB-500 in humans at all, for either sex. What circulates online as "standard" dosing (numbers like 2 to 5 mg per week, split into two injections) comes from anecdotal and compounding-pharmacy practice, not from a controlled trial with dose-ranging data. Because there's no human trial establishing a dose-response curve, there's also no basis for a sex-adjusted dose. Body weight, injury type, and individual response get cited informally as reasons someone might dose lower or higher, but none of that is backed by a study that varied dose and measured outcome in women specifically. If a source gives you a confident, precise "women should use X mg" number, that number is not coming from clinical evidence. It's coming from practice pattern, which is a different and much weaker kind of authority. For a fuller breakdown of the practice patterns people actually follow, see BPC-157 and TB-500 dosing.

Is TB-500 legal, and is it regulated differently for women?

Legal status doesn't change based on the sex of the person using it. TB-500 is not an FDA-approved drug. You can confirm this yourself by searching Drugs@FDA, the FDA's own database of approved drug products ^[9]. It isn't there. Because it's unapproved, TB-500 also isn't on the FDA's 503A bulk drug substances list (the list of substances compounding pharmacies can legally use for human drug compounding) ^[10], nor the 503B list for outsourcing facilities ^[11]. The FDA maintains a public list of substances nominated for 503A compounding that it has evaluated and, in many cases, not added ^[12]. Compounding pharmacies operate under 21 U.S.C. 353a, which sets conditions for pharmacy compounding of drugs for identified patients based on a valid prescription ^[13], and under 21 CFR 216.23 and 216.24, which define the specific bulk substance lists ^{[10] [11]}. None of this framework treats male and female patients differently. It treats the substance the same way regardless of who's receiving it. What does matter is how a product is marketed. Under 21 CFR 201.128, a product's "intended use" (established partly through labeling and claims) determines its regulatory classification, and a compounded preparation marketed for a specific therapeutic use has to fit within that framework ^[14]. Vague "research use only" labels don't change what a product is actually being used for.

How is TB-500 typically sourced, and does that change for women?

Sourcing pathway doesn't split by sex either. TB-500 isn't sold as a standalone product through any legitimate compounding channel. When it's dispensed through a provider-reviewed pathway, it comes as part of a BPC-157/TB-500 blend, prepared by a compounding pharmacy after a prescriber reviews the patient's history and writes for it. That's the model TB-500 Co points readers toward: a provider reviews your case, a prescription gets written if appropriate, and a compounding pharmacy partner fills it as a blend, not a solo TB-500 vial. There's no clinical reason this differs for women versus men. The intake process should ask about the same things for anyone: current medications, other conditions, pregnancy status if relevant, and what you're actually trying to treat. What you should be suspicious of: any seller offering "TB-500 alone" as an injectable product outside a pharmacy relationship, marketed as "research only" while clearly being sold for personal injection. That's a compliance red flag independent of who's buying it.

What does the research say TB-500 might do for injury or wound healing?

The core mechanistic story comes from cell and animal work, not human trials. The 2024 Journal of Chromatography B study screened TB-500 and its metabolites for wound-healing activity in vitro, alongside quantifying the compound in rats ^[1]. That's the kind of study feeding the broader narrative that Tβ4-related peptides support tissue repair, but it's cell culture and rodent pharmacokinetics, several steps removed from a person recovering from a tendon injury. Broader orthopaedic reviews acknowledge peptide therapies are being used clinically in sports medicine settings ahead of the trial evidence catching up. The 2026 JAAOS Global Research & Reviews article frames this explicitly as a field with real "challenges" in the evidence base, alongside genuine applications people are pursuing ^[2]. The American Journal of Sports Medicine primer treats injectable peptide therapy as something orthopaedic and sports medicine physicians need a working knowledge of, precisely because patients are already asking about it or already using it ^[3]. A 2026 Sports Medicine review specifically framed as covering "safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries" is the most direct attempt at weighing this evidence honestly, and its existence signals that the field views current data as insufficient to make strong efficacy claims ^[4]. None of these papers report female-specific outcomes.

Why is TB-500 banned in sports, and does that apply equally to women athletes?

Yes, equally. WADA's prohibited list doesn't have separate rules by sex for peptide hormones and growth factors. TB-500, as a synthetic fragment related to thymosin beta-4, falls under scrutiny in that category, and a substantial amount of published analytical chemistry exists purely because anti-doping labs needed methods to detect it. Multiple papers document this detection effort: liquid chromatography-mass spectrometry methods for TB-500 in equine urine and plasma ^[6], adsorption behavior studies relevant to doping analysis ^[7], analytical approaches for detecting emerging non-approved drugs in human doping controls ^[15], and reviews on detecting peptidic drugs and analogs in sports doping generally ^[16]. Additional work has built in vitro metabolic models for small peptide hormones in drug testing ^[17], compared model systems including liver and kidney microsomes for synthetic doping peptides ^[18], developed screening methods for peptides under 2 kDa by direct urine injection ^[19], tested detection of seven bioactive peptides in horse plasma ^[20], and built solid-phase extraction methods for small peptides from human urine ^[21]. That's a lot of analytical firepower aimed at one substance class. It tells you anti-doping bodies take TB-500 seriously enough to fund detection method development across more than a decade, which is itself a signal about how the substance is classified, regardless of the athlete's sex. If you compete under WADA rules, being female changes nothing about this exposure.

What are the real risks of using TB-500 if you're a woman?

The honest answer is that the specific risks aren't well characterized for anyone, and even less so for women, because the sex-stratified data doesn't exist. Here's what's actually known and unknown, laid out plainly. Known: TB-500 is not FDA approved ^[9], meaning no agency has reviewed a full safety and efficacy dossier for it in humans. Known: it isn't on the FDA's 503A bulk substances list ^[10], so its compounding status sits in a gray zone the FDA has not resolved in the substance's favor. Known: detection methods exist and are actively used in doping control ^{[6] [7] [15]}. Unknown: how it interacts with hormonal contraception, HRT, pregnancy, or breastfeeding. Unknown: whether metabolism differs by sex, body composition, or hormonal status, since the pharmacokinetic work that exists (rats, in vitro models) ^{[1] [17] [18]} wasn't designed to answer that question. Unknown: long-term safety at any dose, in either sex, because no long-duration human trial has been published. If you're weighing this, the honest framing is that you're accepting a real evidence gap, not a demonstrated-safe profile with a data footnote.

Should women pair TB-500 with BPC-157?

This is the pairing most people ask about, and again, there's no controlled trial testing the combination in women or in mixed-sex cohorts. The pairing is popular in practice because BPC-157 and TB-500 are thought to work through different but complementary mechanisms related to tissue repair, but that reasoning comes from mechanistic plausibility and preclinical data on each compound separately, not from a combination trial. In practice, when TB-500 is dispensed through a legitimate compounding pathway, it's typically as a BPC-157/TB-500 blend rather than TB-500 alone, since that's the combination compounding pharmacies are set up to prepare under a prescription. There is no standalone TB-500 product moving through that channel. If you're comparing the two peptides or trying to understand what each is thought to do separately before combining them, BPC-157 vs TB-500 is worth reading before you go further, and BPC-157 and TB-500 dosing covers the practice patterns in more detail.

How do you find a legitimate provider if you're a woman considering TB-500?

Look for a pathway that starts with a provider reviewing your medical history before anything ships. That means questions about current medications, existing conditions, and yes, pregnancy or fertility plans if relevant, more than a checkout page. A legitimate compounding pharmacy operates under the 503A framework, meaning a licensed pharmacist compounds based on a valid patient-specific prescription under 21 U.S.C. 353a ^[13]. That's different from a supplier shipping a vial labeled "research use only" to your house with no prescriber involved anywhere in the chain. TB-500 Co's model points readers toward exactly this kind of provider-reviewed route, where a prescriber evaluates the case and, if appropriate, a compounding pharmacy partner fills the prescription as a BPC-157/TB-500 blend. That's the structure to look for regardless of where you end up getting it: provider first, pharmacy second, never a bare product listing with no clinical review in between. If a site skips straight to checkout without asking about your health history, walk away.

Frequently asked questions

Is there a study specifically on TB-500 in women?

No. No published study isolates female human subjects for TB-500 testing. The existing evidence is preclinical (rat pharmacokinetics, in vitro wound-healing screens) and analytical chemistry work built for doping detection, none of it sex-stratified in a way that answers questions specific to women.

Can TB-500 affect fertility or pregnancy?

There's no published research answering this. No study has tested TB-500's effect on fertility, pregnancy outcomes, or lactation in any species with that specific endpoint. The absence of documented harm isn't the same as evidence of safety; it just means the study hasn't been done.

Is TB-500 the same as thymosin beta-4?

No, they're related but not identical. Thymosin beta-4 is a natural 43-amino-acid protein in the body. TB-500 is a synthetic peptide built around a smaller 7-amino-acid fragment of that protein (specifically the acetylated 17-23 region), studied separately in the analytical chemistry literature.

Does TB-500 dosing differ between men and women?

There's no clinical trial establishing a dose-response relationship for TB-500 in humans of either sex, so there's no evidence-based sex-adjusted dose. Any dosing numbers circulating come from compounding practice patterns, not controlled studies.

Is TB-500 legal to buy and use?

TB-500 is not FDA-approved and isn't on the FDA's 503A or 503B bulk drug substance lists for compounding. It sits in an unresolved regulatory space. Legitimate access runs through a provider who reviews your case and a compounding pharmacy that fills a valid prescription, not direct-to-consumer sales.

Will TB-500 show up on a drug test?

For athletes under WADA testing, yes, potentially. Anti-doping labs have published multiple detection methods for TB-500 in urine and plasma using LC-MS and related techniques, developed specifically because the substance falls under scrutiny in prohibited peptide categories.

Can you buy TB-500 by itself?

Not through a legitimate compounding pathway. TB-500 is typically dispensed as part of a BPC-157/TB-500 blend prepared by a compounding pharmacy under prescription. There is no standalone TB-500 product moving through that channel; anything sold as "TB-500 alone" outside a pharmacy relationship warrants scrutiny.

Does TB-500 interact with birth control or HRT?

No published study has tested this interaction. There's no pharmacokinetic data examining whether hormonal contraception or hormone replacement therapy changes how TB-500 or its metabolites are processed in the body. This is an open question, not a resolved one.

Why do people combine TB-500 with BPC-157?

The two peptides are thought to work through different but complementary mechanisms related to tissue repair, based on separate preclinical data on each. There's no controlled trial testing the combination itself. In practice, compounding pharmacies typically dispense them together as a blend rather than as standalone products.

Is the evidence for TB-500 clinical or preclinical?

Overwhelmingly preclinical. The available data comes from in vitro wound-healing screens, rat pharmacokinetic studies, and doping-detection analytical chemistry. Recent 2026 orthopaedic and sports medicine reviews discuss peptide therapies as a clinical practice area, but they're reviewing a field with thin trial evidence, not reporting new human trial results.

Are there age-related considerations for women using TB-500?

A 2026 Frontiers in Aging review discusses therapeutic peptides broadly in the context of healthy aging mechanisms, but it doesn't isolate TB-500 specifically or report female-specific aging data. Any age-related dosing or safety claim specific to women is not backed by a published study.

What should a woman ask a provider before starting TB-500?

Ask what's actually being prescribed (it will be a BPC-157/TB-500 blend, not TB-500 alone), what compounding pharmacy fills it, whether your full medication and health history was reviewed, and whether pregnancy, fertility plans, or hormonal medications were discussed. If any of that's skipped, that's a red flag.

Sources

1. Journal of Chromatography B, 2024 (PMID 38382158): Quantified TB-500 and its metabolites in vitro and in rats, and screened wound-healing activity in vitro
2. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedics, framing applications alongside challenges in the current evidence base
3. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer on injectable peptide therapy for orthopaedic and sports medicine physicians
4. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries
5. Drug Testing and Analysis, 2012 (PMID 22962027): Synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500
6. Journal of Chromatography A, 2012 (PMID 23084823): Developed LC-MS doping control analysis of TB-500 in equine urine and plasma as a distinct synthetic analyte
7. Analytical Biochemistry, 2017 (PMID 28887173): Studied adsorption effects of doping-relevant peptides including TB-500 in analytical sample handling
8. Frontiers in Aging, 2026 (PMID 42021992): Reviews therapeutic peptide mechanisms and applications for healthy aging in gerontology
9. FDA, Drugs@FDA database: TB-500 does not appear as an FDA-approved drug product
10. 21 CFR 216.23, FDA 503A Bulks List: Defines the bulk drug substances legally permitted for 503A pharmacy compounding, which does not include TB-500
11. 21 CFR 216.24, FDA 503B Bulks List: Defines the bulk drug substances permitted for 503B outsourcing facility compounding
12. FDA, bulk drug substances nominated for 503A compounding: FDA maintains a public list of substances nominated for 503A compounding review, including those not added to the approved list
13. 21 U.S.C. 353a, pharmacy compounding: Sets the statutory conditions under which licensed pharmacists may compound drugs for identified patients based on a valid prescription
14. 21 CFR 201.128, meaning of intended uses: Defines how labeling and marketing claims establish a drug product's intended use for regulatory classification
15. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls
16. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews current status and future directions for detecting peptidic drugs and analogs in sports doping
17. Journal of Peptide Science, 2015 (PMID 25469748): Describes in vitro models used for metabolic studies of small peptide hormones in sport drug testing
18. Journal of Proteomics, 2016 (PMID 27569051): Compared in vitro model systems including liver and kidney microsomes for metabolism of synthetic doping peptides
19. Journal of Separation Science, 2016 (PMID 26578461): Developed a screening method for peptides under 2 kDa by direct urine injection and ion mobility mass spectrometry
20. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): Developed doping control analysis of seven bioactive peptides, including TB-500-related compounds, in horse plasma
21. Drug Testing and Analysis, 2016 (PMID 26472487): Developed solid-phase extraction methods for small biologically active peptides from human urine for doping analysis